Advertisement

Search Results

Advertisement



Your search for Matthew Stenger,Matthew Stenger matches 7009 pages

Showing 101 - 150


breast cancer

Effect of Adjuvant Metformin on Risk of New Primary Cancers in Patients With Early Breast Cancer

In an analysis from the Canadian Cancer Trials Group MA.32 study reported in the Journal of Clinical Oncology, Pamela Goodwin, MD, MSc, FRCPC, FASCO, and colleagues found that adjuvant metformin did not reduce the risk of new primary invasive cancers vs placebo in patients with early breast cancer. ...

gynecologic cancers

Tisotumab Vedotin–Based Combinations in Advanced Cervical Cancer

In a phase Ib/II study (innovaTV 205/GOG-3024/ENGOT-cx8) reported in the Journal of Clinical Oncology, Ignace B. Vergote, MD, PhD, and colleagues found that tisotumab vedotin-tftv combined with carboplatin or pembrolizumab showed activity in both treatment-naive and previously treated patients with ...

skin cancer

Previously Untreated Advanced Melanoma: Addition of Bempegaldesleukin to Nivolumab

In the phase III PIVOT IO 001 trial reported in the Journal of Clinical Oncology, Adi Diab, MD, and colleagues found that the addition of bempegaldesleukin, a pegylated interleukin-2 cytokine prodrug, to nivolumab did not improve treatment outcomes in previously untreated patients with advanced...

gastroesophageal cancer

Addition of First-Line Regorafenib to Nivolumab and Chemotherapy in Metastatic Esophageal Cancer

In a single-institution phase II study reported in The Lancet Oncology, Cytryn et al found that the combination of regorafenib, nivolumab, and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) showed activity as a first-line treatment regimen for patients with HER2-negative metastatic...

leukemia
immunotherapy

Relapsed Pediatric T-Cell ALL: Base-Edited CAR7 T Cells

In an interim analysis of a small phase I study reported in The New England Journal of Medicine, Chiesa et al found that base-edited CAR7 T cells were active in pediatric patients with relapsed T-cell acute lymphoblastic leukemia (ALL). As stated by the investigators: “Cytidine deamination that is...

sarcoma

Localized Ewing Sarcoma: Interval-Compressed vs Standard-Timing Chemotherapy

As reported in the Journal of Clinical Oncology by Cash et al, 10-year follow-up of the Children’s Oncology Group Study AEWS0031 has shown a maintained event-free survival benefit with interval-compressed chemotherapy vs standard-timing chemotherapy in patients with localized Ewing sarcoma....

sarcoma

PD-L1 Inhibition for Advanced Alveolar Soft-Part Sarcoma

In a phase II trial reported in The New England Journal of Medicine, Chen et al found that atezolizumab produced durable responses in patients with advanced alveolar soft-part sarcoma. As stated by the investigators: “Alveolar soft-part sarcoma is a rare soft-tissue sarcoma with a poor prognosis...

head and neck cancer

Dysphagia-Optimized vs Standard IMRT in Newly Diagnosed Patients With Head and Neck Cancer

In the phase III DARS study reported in The Lancet Oncology, Nutting et al found that dysphagia-optimized intensity-modulated radiotherapy (DO-IMRT) was associated with improved patient-reported swallowing function vs standard IMRT in newly diagnosed patients with head and neck cancer. Study...

gynecologic cancers

Selinexor Maintenance Therapy in Advanced or Recurrent Endometrial Cancer

In a phase III study (ENGOT-EN5/GOG-3055/SIENDO) reported in the Journal of Clinical Oncology, Ignace B. Vergote, MD, PhD, and colleagues found that a progression-free survival benefit with maintenance selinexor vs placebo after first-line chemotherapy in patients with advanced or recurrent...

multiple myeloma

Relapsed or Refractory Multiple Myeloma: Mezigdomide Plus Dexamethasone

In a phase I/II trial (CC-92480-MM-001) reported in The New England Journal of Medicine, Paul G. Richardson, MD, and colleagues found that the combination of the novel cereblon E3 ubiquitin ligase modulator mezigdomide and dexamethasone showed activity in heavily pretreated patients with relapsed...

pancreatic cancer

KRAS Wild-Type Advanced Pancreatic Cancer: Addition of Monoclonal Antibody to Chemotherapy

In the Chinese phase III NOTABLE trial reported in the Journal of Clinical Oncology, Shukui Qin, MD, and colleagues examined the addition of the EGFR inhibitor nimotuzumab to gemcitabine in patients with KRAS wild-type locally advanced or metastatic pancreatic cancer. Study Details In the...

head and neck cancer

Can an Anti-EBV Antibody Assist in Screening for Nasopharyngeal Cancer?

In a Chinese study reported in The New England Journal of Medicine, Li et al found evidence that the anti–Epstein-Barr virus (EBV) anti-BNLF2b total antibody, P85-Ab, may be a promising biomarker for nasopharyngeal cancer screening. Study Details In the study, a peptide library representing highly...

issues in oncology
genomics/genetics

Patients With Cancer and DPYD Variant Alleles: Outcomes With Reduced-Dose Fluoropyrimidine Therapy

In an analysis reported in the Journal of Clinical Oncology, Knikman et al found that reduced doses of fluoropyrimidine therapy in patients with cancer with DPYD variant alleles did not result in poorer outcomes vs DPYD wild-type controls receiving full fluoropyrimidine doses. Study Details The...

leukemia

Quizartinib in Newly Diagnosed FLT3-ITD–Positive Acute Myeloid Leukemia

On July 20, 2023, quizartinib was approved for use with standard cytarabine and anthracycline induction and cytarabine consolidation and as maintenance monotherapy following consolidation chemotherapy in adults with newly diagnosed acute myeloid leukemia that is FLT3 internal tandem duplication...

colorectal cancer

Trifluridine/Tipiracil Plus Bevacizumab in Previously Treated Metastatic Colorectal Cancer

On August 2, 2023, the fixed combination of trifluridine, a nucleoside metabolic inhibitor, and tipiracil, a thymidine phosphorylase inhibitor, was approved for use with bevacizumab for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based...

lung cancer

Addition of Nivolumab to Stereotactic Ablative Radiotherapy in Early-Stage or Isolated Lung Parenchymal Recurrent NSCLC

In a phase II trial (I-SABR) reported in The Lancet, Joe Y. Chang, MD, of the Department of Radiation Oncology at The University of Texas MD Anderson Cancer Center, Houston, and colleagues found that the addition of immunotherapy with nivolumab to stereotactic ablative radiotherapy (SABR) improved ...

gynecologic cancers

Dostarlimab-gxly With Chemotherapy for Endometrial Cancer

On July 31, 2023, the immune checkpoint inhibitor dostarlimab-gxly was approved by the U.S. Food and Drug Administration (FDA) for use with carboplatin and paclitaxel, followed by single-agent dostarlimab, for patients with primary advanced or recurrent endometrial cancer that is mismatch...

breast cancer

Neoadjuvant Palbociclib Plus Giredestrant or Anastrozole in ER-Positive, HER2-Negative Breast Cancer

In a phase II study (coopERA Breast Cancer) reported in The Lancet Oncology, Sara A. Hurvitz, MD, and colleagues found that 2 weeks of the addition of neoadjuvant giredestrant—a novel nonsteroidal selective estrogen receptor (ER) degrader—to palbociclib showed a stronger antiproliferative effect...

cns cancers

Cytotoxic and Immune-Stimulatory Gene Therapy for Adults With Primary High-Grade Glioma

In a single-center, phase I, first-in-human trial reported in The Lancet Oncology, Yoshie Umemura, MD, and colleagues investigated treatment with the combination of two adenoviral vectors expressing HSV1-TK (Ad-hCMV-TK) and Flt3L (Ad-hCMV-Flt3L) in adults with primary high-grade glioma. As stated...

cardio-oncology
survivorship

Risk Factors for Incident Heart Failure Among Cancer Survivors Aged 18 to 39

In a study reported in a research letter in JACC: CardioOncology, Hibler et al found that survivors of young adult cancers who were exposed to anthracyclines were at an increased risk of subsequent diagnosis of heart failure. Study Details The study involved electronic health record data from the...

cns cancers

Dabrafenib Plus Trametinib in Relapsed or Refractory BRAF V600–Mutant Pediatric High-Grade Glioma

In a phase II trial reported in the Journal of Clinical Oncology, Hargrave et al found that dabrafenib plus trametinib was highly active in pediatric patients with relapsed or refractory BRAF V600–mutant high-grade glioma. Study Details In the trial, 41 previously treated patients (median age, 13...

hepatobiliary cancer
immunotherapy

Immune Checkpoint Inhibitors for Patients With Child-Pugh Class B vs A Advanced Hepatocellular Carcinoma

In a systematic review and meta-analysis reported in JAMA Oncology, Xie et al explored outcomes associated with immune checkpoint inhibition among patients with advanced hepatocellular carcinoma with Child-Pugh B vs Child-Pugh A liver function. Study Details The analysis included 22 studies...

gynecologic cancers

High-Grade Serous Ovarian Cancer: Impact of Multimodal Screening on Survival

In an analysis of the UKCTOCS study reported in The Lancet Oncology, Menon et al found that patients with high-grade serous tubo-ovarian cancer detected on multimodal screening may have a survival benefit over those whose disease was diagnosed without screening. The investigator stated, “In...

cardio-oncology

Is Cardiovascular Disease Linked to Increased Risk of Cancer?

In a retrospective cohort study reported in JACC: CardioOncology, Bell et al found individuals with a diagnosis of cardiovascular disease were more likely to have a subsequent cancer diagnosis than individuals with no cardiovascular disease diagnosis. Risk was elevated among persons with...

pancreatic cancer
genomics/genetics

Germline Predisposition and Homologous Recombination Deficiency in Pancreatic Acinar Cell Carcinoma

In a study reported in the Journal of Clinical Oncology, Mandelker et al found that pancreatic acinar cell carcinoma was associated with a high prevalence of BRCA2 germline pathogenic variants and genomic features of homologous recombination deficiency (HRD). The study involved somatic and germline ...

myelodysplastic syndromes
genomics/genetics

Allogeneic HCT Outcomes in Patients With MDS and High-Risk Genetics

In a genetic analysis from the Blood and Marrow Transplant Clinical Trials Network 1102 Study reported in the Journal of Clinical Oncology, Versluis et al found that allogeneic hematopoietic cell transplantation (HCT) improved overall survival compared with non-HCT treatment in patients with...

lung cancer

Addition of Tumor Treating Fields Therapy to Standard Systemic Therapy in Metastatic NSCLC After Disease Progression

In a phase III trial (LUNAR) reported in The Lancet Oncology, Leal et al evaluated the addition of tumor treating fields therapy to standard systemic therapy in patients with metastatic non–small cell lung cancer (NSCLC) with disease progression on or after platinum-based chemotherapy. As stated by ...

breast cancer

Receptor Status Among Patients With Invasive Breast Cancer: What’s Missing?

In a study of SEER (Surveillance, Epidemiology, and End Results) data reported in JAMA Network Open, Stephens et al found that approximately 5% of patients with invasive breast cancer had missing components of receptor status and identified several factors associated with the lack of information....

gynecologic cancers
immunotherapy

Platinum-Sensitive Ovarian Cancer: Addition of Atezolizumab to Bevacizumab and Platinum-Based Therapy

In the phase III ATALANTE/ENGOT-ov29 trial reported in the Journal of Clinical Oncology, Kurtz et al found that the addition of atezolizumab to bevacizumab and platinum-based doublets did not significantly improve progression-free survival among patients with platinum-sensitive ovarian cancer....

lymphoma
immunotherapy

DLBCL: Benefit From Polatuzumab Vedotin–Containing Regimens Based on Cell-of-Origin Subtype

In an analysis reported in a letter to the editor in The New England Journal of Medicine, Palmer et al identified evidence that polatuzumab vedotin-piiq–containing regimens were preferentially effective among patients with diffuse large B-cell lymphoma (DLBCL) with activated B cell (ABC) vs...

lung cancer
immunotherapy

Immunochemotherapy Triplet in Patients With Advanced Nonsquamous NSCLC and Untreated Brain Metastases

In a Spanish phase II study (Atezo-Brain; GECP17/05) reported in the Journal of Clinical Oncology, Ernest Nadal, MD, PhD, and colleagues investigated the activity of the combination of atezolizumab with chemotherapy in patients with advanced nonsquamous non–small cell lung cancer (NSCLC) with...

solid tumors
genomics/genetics

Divarasib in Patients With Advanced Solid Tumors and a KRAS G12C Mutation

In a phase I study reported in The New England Journal of Medicine, Sacher et al found that the covalent KRAS G12C inhibitor divarasib (also referred to as GDC-6036) produced durable responses in patients with advanced or metastatic solid tumors with a KRAS G12C mutation. In the study, 137 patients ...

bladder cancer
immunotherapy

Urothelial Carcinoma: Perioperative PD-L1 Inhibition Plus Neoadjuvant Chemotherapy

In a Swiss phase II study (SAKK 06/17) reported in the Journal of Clinical Oncology, Richard Cathomas, MD, and colleagues found that the addition of perioperative durvalumab to neoadjuvant chemotherapy resulted in improved event-free and overall survival in patients with muscle-invasive urothelial...

breast cancer

ER-Positive Breast Cancer: Addition of Adjuvant Ovarian Function Suppression to Tamoxifen in Premenopausal Patients

In an 8-year follow-up of a Korean phase III trial (ASTRRA) reported in the Journal of Clinical Oncology, Baek et al evaluated the effects of adding adjuvant ovarian function suppression to tamoxifen in premenopausal patients with estrogen receptor (ER)-positive breast cancer, with a focus on the...

leukemia
lymphoma

CLL/SLL: Efficacy of CD19-Directed CAR T-Cell Therapy in Relapsed or Refractory Disease

In a phase I/II study (TRANSCEND CLL 004) reported in The Lancet, Tanya Siddiqi, MD, and colleagues found evidence of activity with the CD19-directed chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel in patients with relapsed or refractory chronic lymphocytic leukemia...

skin cancer
immunotherapy

Follow-up of Chronic Immune-Related Adverse Events After Adjuvant Immunotherapy for High-Risk Resected Melanoma

In a retrospective cohort study reported in JAMA Network Open, Goodman et al found that patients receiving adjuvant PD-1 inhibitor therapy for high-risk resected melanoma often had chronic immune-related adverse events, with some persisting over long-term follow-up. Study Details The study included ...

breast cancer

High-Temporal/High-Spatial Resolution Breast MRI for Patients With High Background Parenchymal Enhancement

In a single-center retrospective study reported in the Journal of Clinical Oncology, Eskreis-Winkler et al found that contrast-enhanced magnetic resonance imaging (MRI) using a high-temporal/high-spatial resolution (HTHS) protocol improved breast cancer detection and reduced unnecessary biopsies vs ...

cns cancers

Vorasidenib Improves Progression-Free Survival in IDH1- or IDH2-Mutant Grade 2 Glioma

As reported in The New England Journal of Medicine by Ingo K. Mellinghoff, MD, FACP, and colleagues, the phase III INDIGO trial has shown that vorasidenib, an oral brain-penetrant inhibitor of mutant IDH1 and IDH2 enzymes, significantly improved progression-free survival vs placebo in patients with ...

issues in oncology

Patterns in Early-Onset Cancer Incidence in the United States From 2010 to 2019

In a study using SEER (Surveillance, Epidemiology, and End Results) registry data reported in JAMA Network Open, Koh et al found that the incidence of cancer among individuals in the United States younger than age 50 years—defined as early-onset cancer—increased significantly between 2010 and 2019. ...

prostate cancer

Modified Citrus Pectin Treatment for Nonmetastatic Prostate Cancer

In the long-term treatment phase of an Israeli phase II study reported in the journal Nutrients, Keizman et al found that PectaSol modified citrus pectin (P-MCP) may be effective in patients with nonmetastatic, biochemically relapsed prostate cancer. As stated by the investigators, “[P-MCP] is a...

breast cancer

Pertuzumab/Trastuzumab With or Without Chemotherapy Followed by T-DM1 in HER2-Positive Metastatic Breast Cancer

In an analysis from a phase II European trial reported in JAMA Oncology, Jens Huober, MD, and colleagues found no difference in overall survival with pertuzumab/trastuzumab, with or without chemotherapy, followed by second-line ado-trastuzumab emtansine (T-DM1) in patients with HER2-positive...

issues in oncology
survivorship

Alcohol Consumption Behaviors Among Patients Diagnosed With Cancer

In a study from the National Institutes of Health All of Us Research Program reported in JAMA Network Open, Shi et al found that alcohol consumption and risky drinking behaviors were common among patients with a cancer diagnosis, including patients currently receiving treatment for their cancer....

lung cancer

Addition of Neoadjuvant Monoclonal Antibody to Platinum-Based Chemotherapy in Resectable NSCLC

In a Chinese phase II trial (TD-FOREKNOW) reported in JAMA Oncology, Lei et al found that the addition of neoadjuvant camrelizumab to platinum-based chemotherapy resulted in a higher pathologic complete response rate among patients with resectable stage IIIA or IIIB (T3N2) non–small cell lung...

breast cancer

Targeted Axillary Dissection After Neoadjuvant Therapy in Node-Positive Breast Cancer

In a German prospective registry study (SenTa) reported in JAMA Surgery, Kuemmel et al found that targeted axillary dissection alone after neoadjuvant systemic therapy was associated with outcomes similar to those obtained with targeted axillary dissection plus axillary lymph node dissection in...

lymphoma

Follicular Lymphoma: Novel Drug Combination Shows Benefit

In a phase II trial (ROSEWOOD) reported in the Journal of Clinical Oncology, Zinzani et al found that the addition of zanubrutinib to obinutuzumab significantly improved objective response rate among patients with relapsed or refractory follicular lymphoma. Study Details In the open-label trial,...

prostate cancer

Abiraterone Acetate With or Without Cabazitaxel in Metastatic Prostate Cancer

In a phase II trial reported in the Journal of Clinical Oncology, Slovin et al found that concomitant abiraterone acetate plus prednisone (AAP) and cabazitaxel appeared to produce better outcomes than AAP followed by cabazitaxel upon disease progression in patients with metastatic...

breast cancer

Breast Cancer Screening and 10-Year Net Survival in Canadian Women Aged 40 to 49

In a Canadian study reported in the Journal of Clinical Oncology, Wilkinson et al found that breast cancer screening was associated with greater 10-year breast cancer net survival among women aged 40 to 49 living in jurisdictions including mammography screening programs for this age group, compared ...

skin cancer

Addition of Neoadjuvant Talimogene Laherparepvec to Surgery in Advanced Melanoma: 5-Year Follow-up

As reported in a research letter in JAMA Oncology by Reinhard Dummer, MD, and colleagues, the final, 5-year analysis of a phase II trial showed continued improvement in outcomes with the addition of neoadjuvant talimogene laherparepvec (T-VEC) to surgery in patients with advanced melanoma. Study...

lung cancer

First-Line Cemiplimab vs Chemotherapy in Advanced NSCLC: 35-Month Follow-up of EMPOWER-Lung 1

As reported in The Lancet Oncology by Özgüroğlu et al, extended follow-up of the phase III EMPOWER-Lung 1 trial has shown continued benefit in overall and progression-free survival with first-line cemiplimab-rwlc vs chemotherapy in patients with advanced non–small cell lung cancer (NSCLC) with...

prostate cancer

Radiation Facility Volume and Survival in Very High–Risk Prostate Cancer Treated With Curative Radiation and Androgen-Deprivation Therapy

In a U.S. retrospective cohort study reported in JAMA Network Open, Sebastian et al found that treatment at a high-volume radiation facility was associated with improved overall survival among men with very high–risk prostate cancer receiving curative-intent radiotherapy with androgen-deprivation...

Advertisement

Advertisement



Advertisement